Brachytherapy Doubles Mastectomy Risk And Complications
A breast cancer patient who undergoes brachytherapy has double the chance of losing her breasts compared to one who is treated with whole-breast irradiation, researchers from the MD Anderson Cancer Center, Houston, explained at SABCS (34th Annual San Antonio Breast Cancer Symposium). Brachytherapy is radiation treatment given by placing radioactive material directly in (or near) the target. Brachytherapy simply means internal radiation therapy. For breast cancer patients, a small radioactive source is placed inside the breast after lumpectomy.
Puma Biotechnology Announces Positive PB272 Neratinib Phase II Data At CTRC-AACR San Antonio Breast Cancer Symposium
Puma Biotechnology, Inc., a development stage biopharmaceutical company, announced that results from ongoing Phase II clinical trials of Puma's investigational drug PB272 (neratinib) were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium that is currently taking place in San Antonio, Texas. These presentations are further detailed below: Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With ErbB2-positive Breast Cancer The Phase I/II clinical trial of PB272 given in combination with the chemotherapy drug capecitabine was conducted at numerous locations in the United States, Europe and Asia.
Breast Cancer Prevention - Part Time Low Carb Diet Better Than Standard Full Time Diets
Women who go on a low carb diet just two days per week have a lower risk of developing breast cancer compared to those who follow a standard calorie-restricted diet every day of the week, in order to lose weight and lower their insulin blood levels. Long-term high blood insulin levels are known to raise cancer risk. These findings were presented by scientists from Genesis Prevention Center at University Hospital in South Manchester, England, at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium.